以高血糖伴CA199升高为首发症状的1例亚临床库欣综合征报道并文献复习

Abstract
Figure/Table
References (26)
Related Citation (9)

Download: PDF (692 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract The systemic manifestations of atypical Cushing′s syndrome were studied by detailed inquiry, comprehensive physical examination, biochemical and imaging examination of a newly diagnosed diabetic patient with elevated glycogen antigen 199. The patient had a history of osteoporosis, multiple fractures, hypertension which can be controlled by multi-anti-hypertention drug combination. After the examination, mixed density mass in the lower edge of the lateral branch of the left adrenal gland. Combined with medical history, physical examination, hormone level and imaging results, the citation of the left adrenal adenoma was considered. After laparoscopic excision, the corticosteroid level decreased, blood pressure returned to normal and blood sugar decreased significantly. There are various clinical manifestations of Cushing syndrome, especially for patients′s with subclinical Cushing syndrome, through a comprehensive review of the history, physical examination, hormone evaluation and imaging examination, it is clear that the adrenal occupied space, and through surgical treatment, the patients′ blood glucose, blood pressure and osteoporosis are improved.

Key words： Hyperglycemia Carbohydrate antigen 199 Subclinical Cushing syndrome Atypical manifestations

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Jia

Cite this article:

LI Jia. A case of atypical Cushing syndrome with hyperglycemia and elevated CA199 as the first symptom： a report and literature review[J]. 中国医药导报, 2020, 17(3): 172-175.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I3/172

[1] Mathison DA，Waterhouse CA. Cushing′s syndrome with hypertensive crisis and mixed adrenal cortical adenoma-pheochromocytoma （corticomedullary adenoma） [J]. Am J Med，1969，47（4）：635-641.
[2] 何戎华，陈南衡，陈家伟，等.皮质醇-儿茶酚胺增多症（肾上腺皮质与髓质增生并存一例报告）[J].中华内分泌代谢杂志，1987，3（1）：37，57，69.
[3] 高妍，郭应禄，马文香.嗜铬细胞瘤引起异源性Cushing综合症一例报告[J].中华内分泌代谢杂志，1986，2（2）：46.
[4] 胡卫列.肾上腺皮质髓质混合病变[J].中华腔镜泌尿外科杂志：电子版，2012，6（2）：84-86.
[5] 李乐乐，窦京涛，谷伟军，等.1173例肾上腺意外瘤病因构成分析[J].中华医学杂志，2014，94（8）：587-590.
[6] De Leo M，Cozzolino A，Colao A，et al. Subclinical Cushing′s syndrome [J]. Clin Endocrinol Metab，2012，26（4）：497-505.
[7] Terrolo M，Stigliano A，Chiodini I，et al. AME position statement on adrenal incidentaloma [J]. Eur J Endocrinol，2011，164（6）：851-870.
[8] 李乐乐，赵玲，窦京涛，等.瘤体直径对肾上腺意外瘤性质评估的临床价值[J].中华医学杂志，2017，97（42）：3324-3328.
[9] Beierwaltes WH，Sturman MF，Ryo U，et al. Imaging functional nodules of the adrenal glands with 131-I-19-iodocholesterol [J]. J Nucl Med，1974，15（4）：246-251.
[10] Giordano R，Guaraldi F，Berardelli R，et al. Glucose met-abolism in patients with subclinical Cushing′s syndrome [J]. Endocrine，2012，41（3）：415-423.
[11] Di Dalmazi G，Pasquali R，Beuschlein F，et al. Subclinical hypercortisolism：a state，a syndrome，or a disease? [J]. Eur J Endocrinol，2015，173（4）：M61-M71.
[12] Morelli V，Reimondo G，Giordano R，et al. Long-term follow-up in adrenal incidentalomas：an Italian multicenter study [J]. J Clin Endocrinol Metab，2014，99（3）：827-834.
[13] Inder WJ. Towards a universally accepeted definition of subclinical Cushing′s syndrome-subclinical subtonomous hypercortisolism [J]. Clin Endocrinol，2017，86（1）：7-9.
[14] Debono M，Newell-Price J. Subclinical hypercortisolism in adrenal incidentaloma [J]. Curr Opin Endocrinol Diabetes Obes，2015，22（3）：185-192.
[15] Torlonto M，Zingrillo M，D Aloiso L，et al. Pre-Cushing′s syndrome not recognized by conventional dexamethasone suppression test in an adrenal incidentaloma patient [J]. J Endocrinol Invest，1997，20（8）：501-504.
[16] Wood PJ，Barth JH，Freedman DB，et al. Evidence for the low dose dexamethasone suppression test to screen for Cushing′s syndrome--recommendations for a protocol for biochemistry laboratories [J]. Ann Clin Biochem，1997， 34（3）：222-229.
[17] Orth DN. Cushing′s syndrome [J]. N Engl J Med，1995， 332（12）：791-803.
[18] 李乐乐，韩白玉，窦京涛，等.午夜1mg地塞米松抑制试验对肾上腺意外瘤中亚临床库欣综合征的诊断价值[J].中华医学杂志，2015，95（48）：3912-3916.
[19] Kidambi S，Raff H，Findling JW. Limitations of nocturnal salcary cortisol and urine free cortisol in the diagnosis of mild Cushing′s syndrome [J]. Eur J Endocrinol，2007， 157（6）：725-731.
[20] 张炜，汤正义，王卫庆，等.肾上腺意外瘤中亚临床库欣综合征临床研究[J].中国实用内科杂志，2006，26（7）：516-518.
[21] 张炜，汤正义，王卫庆，等.亚临床及肾上腺腺瘤型库欣综合征患者手术前后代谢综合征症状变化[J].中华内分泌代谢杂志，2006，22（6）：545-548.
[22] 李乐乐，赵玲，窦京涛，等.肾上腺意外瘤中亚临床库欣综合征治疗方案探讨[J].中华医学杂志，2017，97（40）：3152-3157.
[23] Distler M，Pilarsky E，Kersting S，et al. Preoperative CEA and CA199 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas-a retrospective tumor marker prognostic study [J]. Int J Surg，2013，11（10）：1067-1072.
[24] Bauer TM，El-Rayes BF，Li X，et al. Carbohydrate antigen 199 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy： a pooled analysis of 6 prospective trials [J]. Cancer，2013，119（2）：285-292.
[25] Boeck S，Stieber P，Holdenrieder S，et al. Prognostic and therapeutic significance of carbohydrate antigen 199 as tumor marker in patients with pancreatic cancer [J]. Oncology，2006，70（4）：255-264.
[26] Uygur-Bayramicli O，Dabak R，Orbay E，et al. Type 2 diabetes mellitus and CA 199 levels [J]. World J Gastroenterol，2007，13（40）：5357-5359.